Seminars in Pediatric Surgery
Volume 18, Issue 4 , Pages 239-245, November 2009

Omega-3 lipids for intestinal failure associated liver disease

  • Ivan R. Diamond, MD
    • ,
  • Paul B. Pencharz, MBChB, PhD
    • ,
  • Paul W. Wales, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Paul W. Wales, MD, Division of General Surgery, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8 Canada

Group for Improvement of Intestinal Function and Treatment (GIFT), The Hospital for Sick Children, Toronto, Canada

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Competing interests disclosure. The authors have received funding from Fresenius Kabi, the manufacturer of Omegaven®, for an investigator-initiated randomized trial to examine SMOFlipid® for the prevention of IFALD in infants.

PII: S1055-8586(09)00043-2

doi:10.1053/j.sempedsurg.2009.07.005

Seminars in Pediatric Surgery
Volume 18, Issue 4 , Pages 239-245, November 2009

Article Tools